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CLINICAL INVESTIGATION
Improvement of brain function in hemodialysis patients treated
with erythropoietin
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Improvement of brain function in hemodialysis patients treated with
erythropoietin. To evaluate the effects of recombinant human erythro-
poietin (rHuEPO) on brain function, 15 chronic hemodialysis patients
were studied by event-related P300, stimulus-related evoked potentials,
and trailmaking before (hematocrit 22.7%) and after rHuEPO (hemato-
crit 30.6%). P300 peak latency elicited by a tone discrimination para-
digm improved (391 before vs. 366 ms after; Cz = vertex; P < 0.01)
confirming beneficial effects on cerebral cognitive processing. P300
amplitude (13.6 vs. 15.8 V; P = 0.06) and trailmaking tended to
improve (55 vs. 43 s). P300 measures were influenced by low hemoglo-
bin levels before rHuEPO (P < 0,01), suggesting that severe anemia
may contribute to uremic brain dysfunction. Furthermore, decrease of
stimulus-related auditory brainstem I-V interpeak latency (4.28 before
vs. 4.17 ms after; P < 0.05) and increase of somatosensory N20/P25
amplitude (4.8 vs. 7.0 isV; P < 0.05) pointed to improvement of sensory
pathways by mechanisms unrelated to cognition. Brain dysfunction in
chronic hemodialysis patients may, beside other factors, in part be
caused by severe anemia and can be improved by rHuEPO treatment.
Chronic hemodialysis patients may suffer from severe anemia
which is mainly caused by a relative deficiency of erythropoi-
etin [1]. Anemia is responsible for reduced exercise capacity [2]
and may contribute to impairment of quality of life function [31.
Recombinant human erythropoietin (rHuEPO) is effective in
reversing anemia dose dependently, thus improving a sense of
well being [4, 5] and working capacity [6]. However, rHuEPO
treatment implicates potential cerebral risks [4, 5, 7—10] due to
increased blood viscosity and hypertension [11]. Therefore, in
the lack of objective data, the effects of rHuEPO on cerebral
function remain to be studied.
Brain dysfunction is a well known feature in uremic patients
[12, 13] which can be assessed psychometrically, such as, by
the trailmaking test, and by evoked potentials. Evoked poten-
tials representing stable cortical sequences of averaged negative
and positive EEG peaks within a period of several hundred
milliseconds, time-locked elicited by appropriate sensory stim-
uli (stimulus-related) or complex tasks (event-related P300),
were shown to be useful for the evaluation of various neurologic
diseases and cognitive brain dysfunction [14].
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Multimodality short- (<30 ms) and long-latency (>60 ms)
stimulus-related evoked potentials reflecting the functional sta-
tus of corresponding sensory pathways were abnormal in pa-
tients with uremic [15—17] and hepatic encephalopathy [18] with
higher sensitivity than psychometry and/or EEG to detect
subclinical brain dysfunction [19]. Auditory event-related P300
evoked potentials elicited by a tone discrimination paradigm are
objective measures related to information and cognitive proc-
essing [20] allowing a quantification of mental impairment in
demented [21] and psychiatric patients [14]. Assessment by this
technique revealed that glycemic threshold for neuroglycopenia
is markedly higher (72 mg/dl) than generally thought by psy-
chometry and/or EEG (about 55 mg/dl), unequivocally con-
firming the high sensitivity of auditory P300 to detect brain
dysfunction [22]. Accordingly, the P300 technique had potential
for monitoring subclinical neuronal dysfunction in uremic pa-
tients [15].
To evaluate the effects of anemia and partial correction of
anemia by rHuEPO treatment on brain dysfunction, stable
chronic hemodlalysis patients were studied by the trailmaking
test and objective means of stimulus- and event-related P300
evoked potentials before and after rHuEPO treatment.
Methods
Patients
Fifteen chronic hemodialysis patients with transfusion-de-
pendent anemia (51.5 11.8 yrs, mean SD; glomerulonephn-
tis in 6, pyelonephritis in 5, analgesic nephropathy in 2, poly-
cystic kidney disease in 2) were studied before and after
rHuEPO treatment (Table 1). Eleven patients had a history of
hypertension which was well controlled by 1.8 0.6 antihyper-
tensive drugs. Only stable out-patients in good condition with-
out clinical evidence of cognitive deficit as confirmed by "mini-
mental state" scores of 24 [23] were considered for the study.
Diabetics were excluded. rHuEPO treatment was started with
70 15 U/kg thrice weekly (rHuEPO, Boehringer Mannheim,
Indianapolis, Indiana, USA; and Erypo®, Cilag), with gradual
increase of the dose in 6 patients. Finally, 94 27 U/kg were
administered intravenously thrice weekly following hemodialy-
sis sessions. The protocol included assessment of event- and
stimulus-related evoked potentials, psychometric tests and pre-
dialysis blood chemistry. Patients were investigated at least 24
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Table 1A. Characteristics of hemodialysis patients before/after rHuEPO
Patient
No. Sex Age Dialyzera
Blood
OW Kbd KCr BUN
mg/d!
Hk
%
TMA
s
P300
Cz
msmi/mm
1 M 43 F60 195/200 131/127 3/2 77/81 25/28 65/65 381/361
2 M 49 F40 195/195 119/107 4/2 59/56 24/32 39/22 384/372
3 F 41 GFI8OM 190/195 140/134 0/0 100/99 21/25 43/32 410/3%
4 M 56 GFSI2Op 190/200 126/117 2/0 70/81 26/32 35/40 460/435
5 M 59 F60 200/200 133/121 0/0 62/68 22/30 60/35 435/403
6 F 39 GFSI2Op 190/195 130/121 4/3 78/77 24/30 40/40 336/310
7 F 66 GFS12OH 195/200 132/122 0/0 72/64 22/28 45/45 380/365
8 M 46 F60 195/200 135/126 0/0 80/73 23/29 30/24 384/371
9 F 65 F60 195/200 137/121 0/0 59/76 20/30 43/65 384/343
10 M 26 F60 190/195 136/124 0/0 108/131 22/30 35/35 350/300
11 F 62 GFSI2Op 190/195 132/118 2/2 72/68 21/30 30/35 403/360
12 F 54 GFS12OH 190/195 131/1 18 3/2 85/91 21/30 37/45 380/352
13 F 50 F40 195/195 124/102 0/0 95/102 21/36 125/60 379/355
14 M 47 F60 15/195 138/124 010 93/94 19/28 25/28 377/361
15 M 70 GFSI2OH 190/195 116/96 0/0 80/89 29/41 170/75 435/419
Abbreviations are: Hk, hematocrit; TMA, trailmaking test A; P300 Cz, peak latency of auditory event-related evoked potentials.
a F40 (1.25 m2), F60(0.7 m2): Polysulfon, Fresenius, Bad Homburg, FRG; GFI8OM (1.8 m2), GFSI2OH (1.3 m2): Cuprophan, GFS12O plus (1.3
m2): Hemophan, Gambro, Lund, Sweden.
b Urea clearance of dialyzer, derived from mi/mm of plasma water flow
Residual renal function
Table lB. Characteristics of hemodialysis patients treated with rHuEPO
Urea
Blood urea appearance Lean body Trailmaking
Hematocrit Hemoglobin nitrogen rateb massc Fistula test A Mini-mental
% gIdi mg/dl mg/mm kg recirculationd s state
Before rHuEPO 22.7 2.6 7.5 0.9 79 15 6.2 2.5(N=7) 49.8 8.5(N=5) 55 39 27.6 2.2
After rHuEPO 30.6 3.8a 9.5 l.2a 83 18 5.9 2.2(N=7) 43 16(N=5) 3 3(N=7) 43 16 28.1 2.1
Healthy subjects 44.5 5.0k' 5 20b <20 8.1 2.0(N = 24) 59 10(N = 24) 27 8(N = 50) 29.6 0.6(N = 50)
N = 15 (m = 7, f = 8), age 51.5 11.8 yrs; hemodialysis since 2.9 2.5 yrs, 3.9 0.3 hours thrice weekly; rHuEPO: 94 27 U/kg i.v. thrice
weekly; duration of rHuEPO treatment, 4.7 1.2 months.
a P < 0.01 compared to occasion before rHuEPO; according to [24] b and [25] were assessed 4 months (median) after rHuEPOd 5 months after the study
e Mean between male and female; mean SD
hours after routine hemodialysis sessions. Sedatives were with-
drawn. Duration of the study in each individual patient was
limited to six months. Informed consent was obtained from all
patients.
Additionally, six chronic hemodialysis patients without
rHuEPO treatment were studied (48.8 16.0 yrs; pyelonephri-
tis in 3, glomerulonephritis in 2, analgesic nephropathy in 1) on
two different occasions (Table 2). Evoked potential and psy-
chometrical study in patients, control patients and healthy
subjects was performed under comparable conditions.
Patient WM (f, 36 yrs, 3 antihypertensive drugs, blood
pressure <150/90 mm Hg, hematocrit: 22%) dropped out the
study because of renal transplantation. After rejecting the graft
rHuEPO was restarted and hypertension worsened gradually
over weeks. She developed episodes of unconsciousness (blood
pressure 250/140 mm Hg intermittently, hematocrit: 34%) and
had to be mechanically ventilated for four hours. She improved
without sequelae and was well thereafter with a hematocrit kept
at 26%.
Table 2. Characteristics of hemodialysis patients withoUt rHuEPO
Blood
urea Trailmaking Mini-
Hematocrit nitrogen test A mental
% mg/dl s state
Firsta 24.5 1.8 72 23 34 8 29.3 0.8
Second
occasiona
24.5 2.6 70 15 36 9 29.0 0.9
N = 6 (m = 4, f = 2); age, 48.8 16.0 yrs; hemodialysis since
0.6 0.9 yrs.
a Separated by 0.9 0.3 months; mean SD.
Evoked potentials
Evoked potentials were recorded with Ag/AgCl electrodes on
a "Nicolet 2000" according to standard methods [141. For all
calculations of stimulus-related evoked potentials means of
recordings following left and right-sided stimulation were used.
Presentation of findings was focused to the most representative
parameters as shown by Figure 1.
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Fig. 1. Evoked potentials represent stable cortical
sequences of negative and positive EEG peaks,
elicited time-locked by sensory stimuli (stimulus-
related: auditory brainstem, somazosensory short!
long-latency, visual) or complex tasks (event-
related). Generally accepted peak latencies,
interpeak latencies (IPL) (ms) and amplitudes (isV)
were measured before/after rHuEPO: I.) event-
related P300 appears on the rare 2000 Hz tone
record (right) and reflects cognitive processing; 2.)
stimulus-related potentials reflect the functional
status of sensory pathways: I-V LPL, conduction
between acoustic nerve (peak 1) and inferior
colliculus (peak V) of auditory brainstem pathway;
CCT (cervico-cortical time), conduction between
cervical N 13 and cortical N20 peaks of somato-
sensory pathway; P100, conduction of visual
pathway; and Nl-N3(P3) IPL, processing of the
sensory cortical input signal (N20=Nl) by complex
neuro-neuronal interactions (N3,P3). Amplitudes of
somatosensory N20!P25 and visual N75!P 100 were
calculated.
Event-related auditory P300 evoked potentials were gener-
ated following a binaurally presented tone discrimination para-
digm with frequent (80%) tones of 1000 Hz and rare (20%)
target-tones of 2000 Hz delivered at 55 dB HL, recorded at Cz
and Fz, respectively, and referenced to linked mastoids (Al2;
10/20 international system, Fig. 2) [26]. During the paradigm,
the subjects were instructed to keep a running mental count of
the rare 2000 Hz target tones. To verify attention, records with
discrepancy of >10% between actual number of stimuli and
number counted by the patients were rejected. Filter bandpass
was 0.01 to 30 Hz. P300 peak latency (P300 PL; ms), and
amplitude (P300 Amp; V) of rare tones were assessed. Peak
latency was obtained by extrapolating lines from leading and
trailing slopes of P300 peak and measuring the latency at
intersection of lines [21].
Auditory brainstem evoked potentials were elicited by 11.7/s
monoaurally delivered rarefaction clicks of 0.1 ms duration at
75 dB above subject's individual threshold for clicks (maxi-
mum: 90 dB nHL). Filter bandpass was 150 to 3000 Hz. The
active electrode at Cz was referenced to ipsilateral earlobes Al
(A2). Somatosensory short- and long-latency evoked potentials
were elicited by 3.3/s (short) and 1.2/s (long) electrical pulses of
0.2 ms duration with intensities sufficient to produce minimal
thumb twitch, delivered to right and left median nerve at the
wrist, successively. Filter bandpass was 5 to 3000 Hz (short)
and 1 to 1000 Hz (long). Active electrodes at CII (cervical N13)
and 3 cm posterior to C3(4) (cortical N20=short, and
N 1. .N3 ,P3 = long-latency) were referenced to Fz. Visual
evoked potentials were elicited by 1.7/s pattern-reversal
checks, monocularly delivered by a TV screen, 140 cm distant
from the patient's cornea. Visual field subtended 14 degrees of
arc, and individual checks 13 and 54minutes of arc. Intensity of
white and black checks was 77 and 4 cd/rn2, respectively.
Contrast was 72%, filter bandpass 1 to 100 Hz. Active electrode
at Oz was referenced to Fz.
Psychometric tests
"Mini-mental state" [23] and "trailmaking test A" [12] were
performed to test cognitive impairment and psychomotoric
performance. To minimize learning effects, five different trail-
making tables were randomly used [27].
Statistics
Differences between patients before rHuEPO, alter rHuEPO,
and healthy subjects were tested by analysis of variance, levels
Auditory event-related Rare tones
Frequent tones 1000 #2
Auditory brainstem
>
a.
C,,
+
Somatosensory
long-latency
Somatosensory
short-latency Visual
>
>
a.
Al A2
Fig. 2. Position of electrodes used, according to the 10/20 interna-
tional system [26].
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Table 3. Evoked potentials in hemodialysis patients treated with rHuEPO
Auditory event-related .Auditory
brainstem I-V
Somatosensory
Long N l-P3
interpeak
Short-latency
N 13-N20
interpeak N20/P25
.Visual 13 of
arcP300 Cz P300 Cz
Peak lat Amplitude interpeak lat, lat, lat (CCT), amplitude P100 Peak lat
ms ms ms ms pV ms
Before rHuEPO 391 13.6 5.7 4.28 O.3O 88.3 l1.3 5.8 0.6 4.8 3.4 120.8
After rHuEPO
(N = 15) (N = 15)
366 36" 15.8 6.1(N = 15) (N = 15)
(N = 14)
4.17 0.35''(N = 14)
(N = 14)
83.6 9.8(N = 14)
(N = 14) (N = 14)
5.7 0.4 7.0 5.3'(N = 14) (N = 14)
(N = 15)
120.6 7.5"(N = 15)
Healthy subjects 355 30 16.8 4.2(N = 15) (N = 15)
4.02 0.15(N = 50)
79.4 6.5(N = 25)b
5.5 0.4 7.1 4.1(N = 45) (N = 45)
106.6 4.4(N = 50)
Data are means SD. Age-matched healthy subjects: a 51.3 12.2 yrs (sex-matched), b 52.5 10.1 yrs
P < 0.05, 'P < 0.01 compared to occasion before rHuEPO
P < 0.05, P < 0.01 compared to controls
of significance between patients and healthy subjects by
Wilcoxon test, between patients before and after rHuEPO (as
well as in control patients and healthy subjects assessed on two
different occasions) by paired Student's t-tests. Biochemistry,
clinical data, psychometry, and evoked potentials were com-
pared by calculating univariate Pearson's coefficients of cone-
lation and linear multiple regression analysis. For evaluation of
test-retest variability of P300 peak latency coefficients of vari-
ation were calculated in control patients and healthy subjects.
Results
Auditory event-related P300 evoked potentials
Findings of auditory event-related potentials in 15 chronic
hemodialysis patients are shown by Table 3 and indicate that
P300 peak latency improved (decreased; P < 0.01; Cz) by
rHuEPO treatment (not shown by Table 3: P300 peak latency at
Fz: 386 29 before vs. 365 34 ms after; P < 0.01). P300
amplitude tended to improve (increase; P = 0.06; Cz). Improve-
ment of the individual P300 peak latencies by rHuEPO treat-
ment are shown by Figure 3. In contrast, P300 measurements
obtained in six chronic hemodialysis control patients without
rHuEPO were unchanged throughout two different occasions
(peak latency: 358 31 at first vs. 358 27 ms at second
occasion; mean coefficient of variation: 0.8%; amplitude: 15.5
4.5 vs. 15.8 4.4 V; Cz; individual latencies; Fig. 3)
indicating a low intraindividual test-retest variability which was
further confirmed by a low mean coefficient of variation of 2%
obtained in 10 healthy subjects (2 different occasions).
Multimodality stimulus-related evoked potentials
Findings of stimulus-related evoked potentials in chronic
hemodialysis patients are shown by Table 3 and indicate that
auditory brainstem I-V interpeak latency and somatosensory
N20/P25 amplitude improved (P < 0.05) by rHuEPO treatment.
Somatosensory Nl-P3 interpeak latency tended to improve (P
= 0.1). All other evoked potential parameters assessed were not
affected by rHuEPO (not shown by Table 3): somatosensory
N1-N3 interpeak latency (58.5 8.7 before vs. 57.0 8.0 ms
after), N20 peak latency (20.8 1.4 vs. 20.7 1.5 ms), visual
N75/P100 amplitude (10.8 4.6 vs. 10.1 13.8 V, checks 13
mm of arc), P100 peak latency (108.1 6.3 vs. 107.1 7.4 ms,
checks 54 mm of arc) and N75/P100 amplitude (9.8 3.4 vs. 9.8
Age, years
Fig. 3. Individual P300 peak latencies were assessed in 15 hemodialy-
sis patients before (open rhombs) and after rHuEPO-treatment (full
rhombs) demonstrating improvement (decrease) in all patients. In
contrast, latencies were unchanged in 6 hemodialysis controls without
rHuEPO (open circles: first, full circles: second occasions). Full line
represents latency-age regression of 55 healthy subjects (age: 20 to 72
yrs), dotted lines intervals. Assessment before rHuEPO revealed
that 14 of 15 individual P300 peak latencies were beyond the mean (full
line) of healthy subjects and 8 of them near or beyond the upper 2u line.
3.5 V, checks 54 mm of arc). Multimodality stimulus-related
evoked potentials obtained in hemodialysis controls without
rHuEPO were stable throughout two different occasions: audi-
tory brainstem I-V interpeak latency (4.15 0.26 at first vs.
4.18 0.22 ms at second occasion, N = 6), somatosensory
N20/P25 amplitude (6.8 2.9 vs. 6.6 2.9 V, N = 5) and
somatosensory N1-P3 interpeak latency (85.1 6.8 vs. 85.1
5.6 ms, N = 4).
Correlations
Influence of six predictor variables (hemoglobin, hematocrit,
creatinine, blood urea nitrogen, age of patient and duration of
chronic dialysis treatment, years) on four criterion variables
(P300 peak latency, P300 amplitude, trailmaking and "mini-
mental state") was investigated by linear multiple linear regres-
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P300 Latency 0.03/NS NS/NS
P300 Amplitude <0.0l/NS NS/NS
NS/NS NS/NS NS/NS
<0.05/NS <0.0l/NS <0.O5INS
Influence of 6 predictor variables on criterion variables "P300 latency" and "P300 amplitude"; individual probabilities P.
sion analysis (Table 4). The study revealed a significant influ-
ence of "hemoglobin" on P300 peak latency (P < 0.03) and
amplitude (P < 0.01) assessed at low hemoglobin (7.5 gldl)
before rHuEPO treatment. After rHuEPO (at higher hemoglo-
bin of 9.5 gIdI) no influence on P300 measures was found.
Neither trailmaking nor "mini-mental state" before or after
rHuEPO treatment reached any level of significance. There was
no significant correlation between the degree of correction of
anemia and improvement of evoked potentials.
Discussion
This study unequivocally indicates beneficial effects of
rHuEPO treatment on uremic brain dysfunction evaluated by
event-related P300 and stimulus-related evoked potentials.
Such a quantification of mental improvement is of interest,
since rHuEPO treatment may also implicate cerebral risks due
to induced or reestablished hypertension [4, 5, 7—10].
Auditory event-related P300 peak latency improved in hemo-
dialysis patients after rHuEPO treatment (P < 0.01), but was
unchanged in uremic controls and healthy subjects. P300 am-
plitude (P 0.06) and trailmaking tended to improve. Notably,
this beneficial response was achieved by treatment inducing a
moderate partial correction of anemia. Event-related potentials
are objective and valid measures of information and cognitive
processes [20, 211; for example P300 peak latency—increasing
with age in healthy subjects—was related to digit span [281,
cognitive impairment rating [29], rapid evaluation of cognitive
function test [30], orienting [311, stimulus evaluation [32],
selective attention [33], visual pattern recognition [34], and
shown to be useful to assess uremic brain dysfunction [15, 35].
Glycemic threshold for neuroglycopenia was reported to be
higher (72 mg/dl) when assessed by P300 than generally thought
by psychometry and/or EEG (55 mg/dl), indicating markedly
higher sensitivity of this technique to detect brain dysfunction
than sensitivities of the latter methods [22], and stressing
further the validity of our findings. Anecdotally, improvement
of P300 amplitude but not of latency after rHuEPO was re-
ported [36]. This discrepancy may be caused methodically
(such as, cut-off of low-frequency input by different filters used)
or it may indicate that higher hematocrit of that study (37%) has
limited favorable effects in uremic patients.
Multimodality stimulus-related evoked potentials were less
impressive affected by rHuEPO. Peak latencies of early audi-
tory brainstem (I,V) and somatosensory (N20) components
occurring within 20 ms after stimuli are unrelated to cognitive
processing and elicited even under deep sedation [14]. Thus,
slight decrease of auditory I-V interpeak latency and increase of
somatosensory N20/P25 amplitude (P < 0.05) pointed to im-
provement of primary auditory brainstem and somatosensory
pathways. Peak latencies of the later components (somatosen-
sory N3 and P3, visual P100 occurring within 100 ms after
stimuli) are increasingly modified by attention and conscious-
ness, enabling their usefulness for the evaluation of metabolic
encephalopathies [15—19]. Accordingly, somatosensory long-
latency N1-P3 interpeak latency tended to improve by
rHuEPO.
Psychometric tests were widely used in uremic encephalop-
athy [12, 13]. In this study, the "mini-mental state", allowing
an estimate of cognitive function within 10 minutes, was per-
formed to exclude patients with significant impairment (scoring
<24) rather than to monitor such mental changes described due
to its low sensitivity [23]. Trailmaking tests tended to improve
by rHuEPO, but remained unchanged in uremic controls. Bias
by learning effects were unlikely, because different trailmaking
tables were used and time intervals between the tests were long.
Trailmaking, like performance of many other psychometric
tests, is crucially dependent on psychomotoric function limiting
its value as a quantitative measure of cognitive processing
(trailmaking ranged widely from 25 to 170 s, which was not very
likely to be caused by such a wide range of cerebral function).
Since more reliable time-consuming batteries of psychometric
tests are also not without bias [27], and at least in particular
situations less sensitive, evoked potential measurements were
stressed in this study with supplementary use of the well-known
screening psychometry.
Regarding the better P300 findings in the uremic controls than
in rHuEPO-treated patients the favorable overall condition of
the former must be considered: controls were younger, dialyzed
for a shorter period of time, had a higher hematocrit than the
patients and, furthermore, completely normal psychometric
performance. Heterogeneity was mainly caused by estimation
of blood units when patients entered the study. Those patients
with lower hematocrit who were otherwise likely to need blood
were enrolled to the rHuEPO group from ethical aspects, and
the remaining with higher hematocrit to the controls. Neverthe-
less, controls were useful to demonstrate low intraindividual
test-retest variability of evoked potentials in uremic patients.
To investigate the contribution of biochemical and clinical
factors on brain function, regression analysis for six predictors
on the criterion variables P300 and trailmaking was performed.
P300 latency (P < 0.03) and amplitude (P < 0.01) were
influenced by variable hemoglobin when assessed at low hemo-
globin levels before rHuEPO, suggesting that anemia may
contribute to uremic encephalopathy. Although there is no
evidence, it cannot be excluded that these findings could be
confounded by other neuropsychiatric factors. The lack of
correlation with trailmaking may be caused by wide range of
performance. There was no influence of hemoglobin on P300
when assessed at normalized hemoglobin after rHuEPO. This
phenomenon is not surprising, since there is unequivocally no
evidence that hemoglobin levels of normal range may influence
cognition, Since brain dysfunction improved simultaneously
Table 4. Linear multiple regression analysis in hemodialysis patients before/after rHuEPO
Hemoglobin Hematocrit Creatinine BUN Age of pat.
HD
duration
NS/NS
NS/NS
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with rHuEPO administration, it can only be strongly suggested
that this beneficial effect is due to the partial correction of
anemia and not related to other effects. Mental improvement by
blood transfusion in uremic controls might confirm this mech-
anism but could not be provided from an ethical bind. Notably,
changes in neurotransmission [37, 38], brain nitrogen metabo-
lism [39], increased parathyroid hormone and brain Ca2 con-
tent [12], and other factors [40] were reported to be responsible
for uremic encephalopathy, but were not the point of this study.
All patients were in good clinical condition, stable throughout
the study, and most of them worked actively in various profes-
sions. There was no statistical difference of blood urea nitrogen
and creatinine throughout the study which could bias the
favorable mental results. Slightly increased blood urea nitrogen
after rHuEPO was reported also by others [5, 41]. The
rHuEPO-induced increase in hematocrit did not affect efficacy
of hemodialysis in spite of constant dialysis-time, dialyzer, and
blood flow [42]. Urea appearance rate (in 7 patients) was
unchanged by rHuEPO as reported by others [421, indicating
that slightly increased urea after rHuEPO may rather be caused
by decreased urea clearance of dialyzers—a collateral effect of
reduced plasma water flow by increased hematocrit. Un-
changed lean body mass (in 5 patients) pointed to a stable
nutritional state.
Our results confirm short reports of beneficial mental effects
after rHuEPO [36, 43] and are in line with findings of increased
sense of well being [4, 5, 7], quality of life [44, 45], and working
capacity [6]. However, as shown by patient WM (before
rHuEPO: P300 abnormal; all stimulus-related evoked potentials
and trailmaking normal) who dropped out the study because of
kidney transplantation and who developed hypertensive crisis
after returning to rHuEPO, rHuEPO may be harmful in poorly
controlled hypertension. Such patients require vigorous antihy-
pertensive treatment and a moderate correction of anemia just
sufficient to avoid further transfusions.
In conclusion, brain dysfunction in chronic hemodialysis
patients improved by rHuEPO treatment. Mental improvement
was confirmed quantitatively by evoked potential measure-
ments. Severe anemia may, beside other factors, contribute to
uremic brain dysfunction.
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